Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...

“Marketresearch.biz reports that the Ataxia market was valued at USD 11,558.3 million in 2023. It is expected to reach USD 20,778.5 million by 2033, with a CAGR of 6.20% during the forecast period ...

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from ...

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data ...

Judge Rebecca A. Sanders, chair of the Workers Compensation Appeals Board of the Kansas Department of Labor, Topeka, is the ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

The Movement festival kicks off today at Hart Plaza in Detroit. Here's the opening day artist schedule, listed by times. 2 ...

But 15 years ago, he met a patient whom he thought could be the key to solving a decade-long mystery. The patient had ...

Spinocerebellar ataxia type 4 (SCA4), while not widely known due to its rarity, has been a subject of intense investigation.